Morbidity associated with stress ulcer–related bleeding, the cost of medications, and the possible complications associated with stress ulcer prophylaxis are important considerations when prescribing prophylaxis. We prospectively studied the prescription patterns for stress ulcer prophylaxis in patients admitted to our ICU.
Methods:
We prospectively recorded the indications for stress ulcer prophylaxis and prescription patterns for use based on the American Society of Healthcare Pharmacists criteria and other indications for 99 new intensive care unit (ICU) admissions to a tertiary referral center.
Results:
In all 51 patients had no indication for stress ulcer prophylaxis, 32 had 1 indication, 14 had 2 indications, and 2 patients had 3 indications for receiving stress ulcer prophylaxis in the ICU. Eighty-two percent of patients without any indications received stress ulcer prophylaxis; 81% of patients with 1 indication, 79% of patients with 2 indication, and 50% of patients with 3 indications received stress ulcer prophylaxis. Overall, 53% of patients either received stress ulcer prophylaxis when none was indicated or did not receive stress ulcer prophylaxis when it was indicated. We also review the recent literature on stress-related mucosal disease and the use of prophylaxis for stress-related mucosal disease.
Conclusions:
Stress ulcer prophylaxis administration in this ICU is inconsistent and includes both underutilization and overutilization. Educating physicians and implementing hospital protocols could improve use patterns.
CookDJFullerHDGuyattGH. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994;330(6):377–381.
2.
CookDJGriffithLEWalterSD; Canadian Critical Care Trials Group. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care. 2001;5(6):368–375.
3.
EomCSJeonCYLimJWChoEGParkSMLeeKS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310–319.
4.
ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56(4):347–379.
EllisonRTPerez-PerezGWelshCH. Risk factors for upper gastrointestinal bleeding in intensive care unit patients: role of Helicobacterpylori. Federal Hyperimmune Immunoglobulin Therapy Study Group. Crit Care Med. 1996;24(12):1974–1981.
7.
FusamotoHHagiwaraHMerenH. A clinical study of acute gastrointestinal hemorrhage associated with various shock states. Am J of Gastroenterol. 1991;86(4):429–433.
8.
CzajaAJMcAlhanyJCPruittBA.JrAcute gastroduodenal disease after thermal injury. An endoscopic evaluation of incidence and natural history. N Engl J Med. 1974;291(18):925–929.
9.
BrownTHDavidsonPFLarsonGM. Acute gastritis occurring within 24 hours of severe head injury. Gastrointest Endosc. 1989;35(1):37–40.
10.
GoodmanAAFreyCF. Massive upper gastrointestinal hemorrhage following surgical operations. Ann Surg. 1968;167(2):180–184.
11.
LucasCESugawaCRiddleJRectorFRosenbergBWaltAJ. Natural history and surgical dilemma of “stress” gastric bleeding. Arch Surg. 1971;102(4):266–273.
12.
PeuraDAJohnsonLF. Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Inter Med. 1985;103(2):173–177.
13.
PoleskiMHSpanierAH. Cimetidine versus antacids in the prevention of stress erosions in critically ill patients. Am J Gastroenterol. 1986;81(2):107–111.
14.
DuerksenDR. Stress-related mucosal disease in critically ill patients. Best pract Res Clin Gastroenterol. 2003;17(3):327–344.
15.
SeslerJM.Stress-related mucosal disease in the intensive care unit: an update on prophylaxis. AACN Adv Crit Care. 2007;18(2):119–126;quiz 127-118.
16.
MutluGMMutluEAFactorP. GI complications in patients receiving mechanical ventilation. Chest. 2001;119(4):1222–1241.
17.
FennertyMB. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. Crit Care Med. 2002;30(6 suppl):S351–S355.
18.
SchusterDPRowleyHFeinsteinSMcGueMKZuckermanGR. Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med. 1984;76(4):623–630.
19.
YasueNGuthPH. Role of exogenous acid and retransfusion in hemorrhagic shock-induced gastric lesions in the rat. Gastroenterology. 1988;94(5 pt 1):1135–1143.
20.
AliTHartyRF. Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin North Am. 2009;38(2):245–265.
LinPCChangCHHsuPITsengPLHuangYB. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med. 2010;38(4):1197–1205.
23.
CookDGuyattGMarshallJ. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998;338(12):791–797.
24.
GrubeRRMayDB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm. 2007;64(13):1396–1400.
25.
HeidelbaughJJInadomiJM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101(10):2200–2205.
26.
Pitimana-areeSForrestDBrownGAnisAWangXHDodekP. Implementation of a clinical practice guideline for stress ulcer prophylaxis increases appropriateness and decreases cost of care. Intensive Care Med. 1998;24(3):217–223.
27.
NasserSCNassifJGDimassiHI. Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World J Gastroenterol. 2010;16(8):982–986.
28.
PerwaizMKPosnerGHammoudehF. Inappropriate Use of Intravenous PPI for Stress Ulcer Prophylaxis in an Inner City Community Hospital. J Clin Med Res. 2010;2(5):215–219.
29.
AlsultanMSMayetAYMalhaniAAAlshaikhMK. Pattern of intravenous proton pump inhibitors use in ICU and Non-ICU setting: a prospective observational study. Saudi J Gastroenterol. 2010;16(4):275–279.
30.
GuptaRGargPKottoorR. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103:207–211.
31.
FarrellCPMercoglianoGKuntzCL. Overuse of stress ulcer prophylaxis in the critical care setting and beyond. J Crit Care. 2010;25(2):214–220.
32.
WohltPDHansenLAFishJT. Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother. 2007;41(10):1611–1616.
33.
SchuppKNSchrandLMMutnickAH. A cost-effectiveness analysis of stress ulcer prophylaxis. Ann Pharmacother. 2003;37(5):631–635.
34.
DialSDelaneyJABarkunANSuissaS. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–2995.
35.
KimJWLeeKLJeongJB. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol. 2010;16(28):3573–3577.
36.
LiXQAnderssonTBAhlstromMWeidolfL. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821–827.
